Verve Therapeutics (VERV) said Monday its investigational new drug application for Verve-102 has been cleared by the US Food and Drug Administration to treat heterozygous familial hypercholesterolemia and/or premature coronary artery disease.
Verve-102 is an investigational in vivo base editing medicine that inactivates the PCSK9 gene in liver to reduce blood low-density lipoprotein cholesterol designed to be effective in one course of treatment, the company added.
The regulator's decision was based on the company's interim clinical data from the dose-escalation part of the current Heart-2 phase 1b clinical study for Verve-102, Verve said, adding that it intends to report demographic and initial safety and efficacy data from the Heart-2 clinical trial in Q2.
The company expects to post final data for the dose escalation portion of the Heart-2 clinical trial in H2.
Verve's stock was up 1.1% in recent Monday premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。